SCIENCE@home

Brazilian recommendations for the management of tuberculosis infection in immune-mediated inflammatory diseases

V. A. de Souza,Ana Luíza Mendes Amorim Caparroz,V. Trevisani,Anna Carolina F.M. Gomes Tavares,Ana Karla Guedes de Melo,Anete Trajman,A. Medeiros-Ribeiro,M. Pinheiro,R. Xavier,O. Monticielo,Maria Fernanda Brandão de Resende Guimarães,F. Sztajnbok,S. Bombarda,L. Chebli,A. Kakehasi,A. Bierrenbach,A. P. M. Gomides Reis,Blanca Elena Rios Gomes Bica,Claudia Diniz Lopes Marques,C. Flores,D. Rodrigues,E. Paiva,Eliana Dias Matos,Fernanda Dockhorn Costa Johansen,H. Bacha,Joana Starling de Carvalho,J. Provenza,Ketty Lysie Libardi Lira Machado,Licia Maria Henrique da Mota,L. D. Valadares,Marco Antônio Araújo da Rocha Loures,Margareth Maria Pretti Dalcolmo,Maria Cecilia de Carvalho Bortoletto,Max Igor Banks Ferreira Lopes,Rejane Maria R. Abreu Vieira,Ricardo Romiti,Rogerio Saad-Hossne,R. Ciconelli,Valderílio Feijó Azevedo,V. M. Augusto,Vitor Alves Cruz,G. Salviato Pileggi

Published 2025 in Advances in Rheumatology

ABSTRACT

The risk of tuberculosis infection (TBI) and its progression to tuberculosis disease (TBD) among persons with immune-mediated inflammatory diseases (IMID) results from a complex interplay of patient and disease characteristics, immunosuppression level, and the epidemiological context. Brazilian recommendations are unclear about TBI screening and its preventive treatment (TPT) in persons with IMID. To provide a comprehensive and evidence-based guideline for managing TBI in persons with IMID in Brazil. This task force was constituded by 42 specialists with interest in IMID and TBD. A core leadership team (CLT) drafted fourteen clinical questions on the risk of tuberculosis and indications of TPT among persons with IMID who started, or are about to start immunosuppressive drugs. The CLT supervised the systematic reviews and formulated the recommendations. The experts voted using the Delphi Method. Nine recommendations were established. More than 80% of panelists voted “agree” and “strongly agree” with all statements. In brief, all persons with IMID starting or about to start immunosuppressive treatment should undergo tuberculin skin testing (TST) or interferon-gamma release assays (IGRAs), a chest imaging test and investigation of contact with active pulmonary or laryngeal TBD. TPT is mandatory for those with any positive result after excluding TBD. Exceptions include individuals with a history of TBD or a past positive TBI infection test. IGRA is preferred only in persons BCG-vaccinated in the past 2 years. Those with inconclusive IGRA results can have the test repeated once, and TPT should be offered if it remains indeterminate. TST or IGRA should be repeated yearly, for three years, when the previous test was negative, when starting or changing to a different class of immunosuppressive drug. Overall, the included studies had a low quality of evidence and high risk of bias. These guidelines are meant to improve the management of TBI in IMID. Health professionals must consider the epidemiological risk, host features, the social scenario, the characteristics of the disease, the access to health resources, and the development of an individualized plan for every patient.

PUBLICATION RECORD

CITATION MAP

EXTRACTION MAP

CLAIMS

  • No claims are published for this paper.

CONCEPTS

  • No concepts are published for this paper.

REFERENCES

Showing 1-54 of 54 references · Page 1 of 1

CITED BY

Showing 1-4 of 4 citing papers · Page 1 of 1